• Yukio Ago, Naoki Hiramatsu, Toshihiro Ishihama, Keisuke Hazama, Atsuko Hayata-Takano, Yasuhiro Shibasaki, Norihito Shintani, Hitoshi Hashimoto, Toshiyuki Kawasaki, Hirotaka Onoe, Shigeyuki Chaki, Atsuro Nakazato, Akemichi Baba, Kazuhiro Takuma, and Toshio Matsuda.
• Japan Society for the Promotion of Science, Tokyo, Japan.
• Behav Pharmacol. 2013 Feb 1; 24 (1): 74-7.

AbstractPrevious studies suggest that metabotropic glutamate 2/3 receptors are involved in psychiatric disorders. In this study, we examined the effects of the selective metabotropic glutamate 2/3 (mGlu2/3) receptor agonist MGS0028 on behavioral abnormalities in mice lacking the pituitary adenylate cyclase-activating polypeptide (PACAP), an experimental model of psychiatric disorders such as schizophrenia and attention-deficit/hyperactivity disorder. We found that PACAP-deficient mice showed impairments in the novel object recognition test and these impairments were improved by MGS0028 (0.1 mg/kg). Similarly, MGS0028 improved hyperactivity and jumping behaviors, but did not reverse increased immobility times in the forced swim test in PACAP-deficient mice. These results suggest that MGS0028 may be a potential, novel treatment for psychiatric disorders.

38 keywords...

hide…